Can acyclovir induce hepatic injury, and what is the recommended management if transaminases become elevated?

Acyclovir and Liver Injury

Yes, acyclovir can cause hepatic injury, though this is rare; if transaminases become elevated, the drug should be discontinued and the patient monitored closely, with reintroduction only after liver function normalizes and alternative causes are excluded.

Can Acyclovir Cause Liver Injury?

While the FDA label for acyclovir does not specifically list hepatotoxicity as a prominent adverse effect, the drug can cause liver injury 1. The primary warnings focus on renal toxicity and neurological complications, but hepatic dysfunction remains a recognized concern in clinical practice. Acyclovir is metabolized hepatically and requires caution in patients with underlying liver disease.

Clinical Presentation and Recognition

Acyclovir-related liver injury typically presents as:

• Asymptomatic transaminase elevations (most common)
• Hepatocellular pattern of injury (elevated ALT/AST disproportionate to alkaline phosphatase)
• Symptoms may include severe fatigue, nausea, vomiting, or right upper quadrant pain 1

The key is distinguishing drug-induced liver injury from other causes, as transaminase elevations occur in approximately 10-20% of the general population and have multiple etiologies 2.

Management Algorithm for Elevated Transaminases on Acyclovir

Step 1: Assess the Severity

For ALT/AST < 2× ULN:

• Continue acyclovir if clinically necessary
• Recheck liver function in 2 weeks
• If levels rise above 2× ULN, proceed to closer monitoring

For ALT/AST 2-5× ULN:

• Monitor liver function weekly for 2 weeks, then every 2 weeks until normalized 3
• Maintain adequate hydration 1
• Assess for symptoms (fever, malaise, vomiting, jaundice)

For ALT/AST ≥ 5× ULN or any elevation in bilirubin:

• Stop acyclovir immediately 3
• This threshold indicates moderate-to-severe liver injury requiring drug discontinuation 4

Step 2: Investigate Alternative Causes

Perform comprehensive evaluation including:

• Viral hepatitis serologies: HBV, HCV, HAV, HEV, EBV, CMV 4
• Autoimmune markers: ANA, anti-smooth muscle antibody, immunoglobulins
• Metabolic screening: Iron studies (ferritin, TIBC), ceruloplasmin, alpha-1 antitrypsin
• Other hepatotoxins: Review all concomitant medications, alcohol use, herbal supplements 2, 5
• Imaging: Ultrasound to exclude biliary obstruction or structural abnormalities

Step 3: Clinical Monitoring

If acyclovir is stopped:

• Monitor liver function tests twice weekly initially 4
• Assess for clinical symptoms: jaundice, coagulopathy, encephalopathy
• Most drug-induced liver injury improves within 2-8 weeks of drug cessation 6

If patient is critically ill and acyclovir is essential:

• Weigh risk-benefit ratio carefully
• Consider alternative antiviral agents (valacyclovir, famciclovir) if available, though cross-reactivity may occur 7
• Provide supportive care with close monitoring in hospital setting

Step 4: Rechallenge Considerations

Do NOT rechallenge if:

• ALT/AST exceeded 5× ULN
• Bilirubin was elevated
• Patient had symptoms of hepatic dysfunction
• Alternative antiviral options are available

May consider rechallenge only if:

• Elevation was mild (2-3× ULN) and asymptomatic
• Liver function has completely normalized
• No alternative cause was identified
• Clinical need is compelling and no alternatives exist
• Patient provides informed consent and close monitoring is feasible

Important Caveats and Pitfalls

Common Pitfalls:

• Assuming all transaminase elevations are drug-related: Many patients have underlying metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis, or other causes 2
• Continuing potentially hepatotoxic drugs beyond safe thresholds: The 5× ULN threshold is critical for drug discontinuation 3, 4
• Inadequate hydration: Acyclovir requires adequate hydration to prevent renal tubular precipitation, which can secondarily affect liver function 1

Special Populations:

• Renal impairment: Dose adjustment is mandatory; accumulation increases toxicity risk 1
• Concomitant nephrotoxic agents: Increased risk of both renal and hepatic complications 1
• Immunocompromised patients: Higher baseline risk of hepatotoxicity and complications 1

Monitoring Frequency: Patients on potentially hepatotoxic medications should have liver function monitored twice weekly initially, particularly those with pre-existing liver disease or abnormal baseline tests 4.